VKTX vs. ITCI, ASND, JAZZ, CERE, BPMC, LEGN, CYTK, ELAN, OGN, and BBIO
Should you be buying Viking Therapeutics stock or one of its competitors? The main competitors of Viking Therapeutics include Intra-Cellular Therapies (ITCI), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Cerevel Therapeutics (CERE), Blueprint Medicines (BPMC), Legend Biotech (LEGN), Cytokinetics (CYTK), Elanco Animal Health (ELAN), Organon & Co. (OGN), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical preparations" industry.
Intra-Cellular Therapies (NASDAQ:ITCI) and Viking Therapeutics (NASDAQ:VKTX) are both mid-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends, media sentiment, valuation and community ranking.
Intra-Cellular Therapies presently has a consensus price target of $90.17, indicating a potential upside of 37.41%. Viking Therapeutics has a consensus price target of $112.38, indicating a potential upside of 71.93%. Given Intra-Cellular Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Viking Therapeutics is more favorable than Intra-Cellular Therapies.
92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 3.4% of Intra-Cellular Therapies shares are held by company insiders. Comparatively, 4.7% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Intra-Cellular Therapies has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the S&P 500.
Viking Therapeutics has lower revenue, but higher earnings than Intra-Cellular Therapies. Viking Therapeutics is trading at a lower price-to-earnings ratio than Intra-Cellular Therapies, indicating that it is currently the more affordable of the two stocks.
Viking Therapeutics received 95 more outperform votes than Intra-Cellular Therapies when rated by MarketBeat users. Likewise, 79.87% of users gave Viking Therapeutics an outperform vote while only 67.38% of users gave Intra-Cellular Therapies an outperform vote.
Viking Therapeutics has a net margin of 0.00% compared to Viking Therapeutics' net margin of -21.57%. Intra-Cellular Therapies' return on equity of -18.41% beat Viking Therapeutics' return on equity.
In the previous week, Viking Therapeutics had 6 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 13 mentions for Viking Therapeutics and 7 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 1.06 beat Viking Therapeutics' score of 0.88 indicating that Viking Therapeutics is being referred to more favorably in the news media.
Summary
Viking Therapeutics beats Intra-Cellular Therapies on 13 of the 17 factors compared between the two stocks.
Get Viking Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VKTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Viking Therapeutics Competitors List
Related Companies and Tools
